Table 1.
Activities of compounds in the screening assay.
| Compound | Concentration at T50 = 350 min mean ± s.d. (n) | |
|---|---|---|
| µM | mg/L | |
| Inositol phosphate derivatives | ||
| OEG2-IP5 | 7.9 ± 2.7 (3) | 7.1 ± 2.4 (3) |
| OEG7-IP5 | 6.7 ± 0.9 (3) | 7.6 ± 1.0 (3) |
| OEG11-IP5 | 5.3 ± 0.7 (3) | 6.8 ± 0.9 (3) |
| OEG12-IP5 | 4.9 ± 0.6 (5) | 6.6 ± 0.9 (5) |
| (OEG2)2-IP4 | 4.9 ± 0.8 (6) | 4.3 ± 0.7 (6) |
| (OEG7)2-IP4 | 4.5 ± 0.4 (3) | 6.0 ± 0.6 (3) |
| (OEG11)2-IP4 | 3.8 ± 0.3 (3) | 6.3 ± 0.6 (3) |
| OEG11-IP2S3 | 18.6 ± 1.9 (5) | 22.9 ± 2.3 (5) |
| (OEG2)3-IP3 | 7.1 ± 0.9 (3) | 5.4 ± 0.7 (3) |
| (OEG7)3-IP3 | 9.4 ± 0.6 (3) | 14.3 ± 1.0 (3) |
| Inositol controls | ||
| myo-Inositol | >100 (4) | >18.0 (4) |
| IP2 | 35.0 ± 7.7 (3) | 15.0 ± 3.3 (3) |
| IP3 | 18.6 ± 3.1 (3) | 10.2 ± 1.7 (3) |
| IP4 | 19.5 ± 0.7 (3) | 13.2 ± 0.5 (3) |
| IP5 | 13.2 ± 1.3 (3) | 10.5 ± 1.0 (3) |
| IT6 | 14.4 ± 0.3 (3) | 36.14 ± 0.24 (3) |
| ITPP | >100 (4) | >60.6 (4) |
| Known inhibitors of calcification | ||
| IP6 | 35.0 ± 9.9 (26) | 30.9 ± 8.7 (26) |
| Magnesium citrate | >100 (3) | >21.4 (3) |
| PPi | 27.4 ± 2.8 (3) | 7.3 ± 0.8 (3) |
| Etidronate | 10.5 ± 1.1 (4) | 2.6 ± 0.3 (4) |
| Alendronate | 9.9 ± 1.0 (6) | 3.2 ± 0.3 (6) |
| Others | ||
| PEG-alendronate | 12.3 ± 3.0 (3) | 28.1 ± 6.9 (3) |